Company profile
AURINIA PHARMACEUTICALS INC.
NASDAQ:AUPHBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LUPKYNIS | approved | $79.4MQ2 2026 | 14 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00258713 | phase3 | completed | 2005-09-01 | 2006-07-01 | Aurinia Pharmaceuticals Inc. | A 36-Week Extension to Protocol ISA04-03 |
| NCT02141672 | phase2 | completed | 2014-06-01 | 2016-07-01 | Aurinia Pharmaceuticals Inc. | AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) |
| NCT02949973 | phase2 | completed | 2015-06-01 | 2016-12-01 | Aurinia Pharmaceuticals Inc. | Aurinia Early Urinary Protein Reduction Predicts Response |
| NCT03597464 | phase3 | completed | 2019-09-29 | 2021-10-07 | Aurinia Pharmaceuticals Inc. | Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin |
| NCT03021499 | phase3 | completed | 2017-05-17 | 2019-09-24 | Aurinia Pharmaceuticals Inc. | Aurinia Renal Response in Active Lupus With Voclosporin |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 213716 | 2021-01-22 | NDA | AURINIA PHARMACEUTICALS INC | |||||
Loading… | ||||||||